The company will engage in BIO One-on-One Partnering™ meetings as it advances Phase 1 for Ketamir-2, prepares Phase IIa study ...

The company will compete with a device Boston Scientific acquired for $850 million.

For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and ...

TFC Financial Management Inc. raised its holdings in Boston Scientific by 308.8% during the ... movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary ...

Boston Scientific ... rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment ...

Baker currently serves as chief medical officer of Neuromodulation at Boston Scientific, showcasing 35 years of pain management leadership. Arsenal’s CEO sees Baker’s arrival as timely, given their ...

Boston Scientific has proven ... in spinal cord stimulation for chronic pain. The 2020 dip in profitability due to covid notwithstanding, management's efforts to streamline operations and enhance ...

Get to Know Boston Scientific ... management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and ...